Test ID VITE Vitamin E, Serum
Shipping Instructions
Ship specimen in amber vial to protect from light.
Specimen Required
Patient Preparation: Fasting overnight (12-14 hours) (infants-draw prior to next feeding)
Supplies: Amber Frosted Tube, 5 mL (T915)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Amber vial
Specimen Volume: 0.5 mL
Collection Instructions: Within 24 hours of collection, centrifuge, and aliquot serum into an amber vial to protect from light.
Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.
Secondary ID
42358Useful For
Evaluation of individuals with motor and sensory neuropathies
Monitoring vitamin E status of premature infants requiring oxygenation
Evaluation of persons with intestinal malabsorption of lipids
Method Name
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Vitamin E, SSpecimen Type
SerumSpecimen Minimum Volume
0.25 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 44 days | LIGHT PROTECTED |
Frozen | 44 days | LIGHT PROTECTED | |
Ambient | 7 days | LIGHT PROTECTED |
Clinical Information
Vitamin E (alpha-tocopherol) contributes to the normal maintenance of biomembranes, the vascular and nervous systems, and provides antioxidant protection for vitamin A. The level of vitamin E in the plasma or serum after a 12- to 14-hour fast reflects the individual's reserve status.
The current understanding of the specific actions of vitamin E is very incomplete. The tocopherols (vitamin E and related fat-soluble compounds) function as antioxidants and free-radical scavengers, protecting the integrity of unsaturated lipids in the biomembranes of all cells and preserving retinol (vitamin A) from oxidative destruction. Vitamin E is known to promote the formation of prostacyclin in endothelial cells and to inhibit the formation of thromboxanes in thrombocytes, thereby minimizing the aggregation of thrombocytes at the surface of the endothelium. Those influences on thrombocyte aggregation may be of significance in relation to risks for coronary atherosclerosis and thrombosis.
Deficiency of vitamin E in children leads to reversible motor and sensory neuropathies; this problem has also been suspected in adults. Premature infants who require an oxygen-enriched atmosphere are at increased risk for bronchopulmonary dysplasia and retrolental fibroplasia; supplementation with vitamin E has been shown to lessen the severity of, and may even prevent, those problems.
Deficiencies of vitamin E may arise from poor nutrition or from intestinal malabsorption. At-risk persons, especially children, include those with bowel disease, pancreatic disease, chronic cholestasis, celiac disease, cystic fibrosis, and intestinal lymphangiectasia. Infantile cholangiopathies that may lead to malabsorption of vitamin E include intrahepatic and extrahepatic biliary atresia, paucity of intrahepatic bile ducts, arteriohepatic dysplasia, and rubella-related embryopathy. In addition, low blood levels of vitamin E may be associated with abetalipoproteinemia, presumably due to a lack of the ability to form very low-density lipoproteins and chylomicrons in the intestinal absorptive cells of affected persons.
Vitamin E toxicity has not been established clearly. Chronically excessive ingestion has been implicated as a cause of thrombophlebitis, although this has not been definitively verified.
Reference Values
0-17 years: 3.8-18.4 mg/L
≥18 years: 5.5-17.0 mg/L
Cautions
Testing of nonfasting specimens or the use of vitamin supplementation can result in elevated serum vitamin concentrations. Reference values were established using specimens from individuals who were fasting.
Day(s) Performed
Monday through Friday
Report Available
3 to 5 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
84446